GRI Bio Featured in "Why Now" On-Demand Video Webcast

LA JOLLA, CA, Aug. 27, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company developing innovative therapies for inflammatory, fibrotic and autoimmune diseases, today announced that it is featured in a "Why Now" video webcast.

During the webcast, Marc Hertz, Ph.D., Chief Executive Officer of GRI Bio, discusses the Company's differentiated approach to treating idiopathic pulmonary fibrosis (IPF) through GRI-0621, a once-daily oral, RARβ/γ-selective agonist designed to modulate the biological pathways associated with inflammation, fibrosis and tissue repair. The discussion also highlights GRI-0621's differentiated mechanism of action and the significant unmet need that remains for patients living with IPF. As previously announced, GRI has been selected for presentation at the 2026 European Respiratory Society (ERS) Congress, being held September 5-9 in Barcelona, Spain, where it will present on data that it believes is supportive of GRI-0621’s differentiated mechanism and its potential to address the underlying biology of IPF.